217 related articles for article (PubMed ID: 22881437)
21. The effect of budesonide and formoterol in one pressurized metered-dose inhaler on patient-reported outcomes in adults with mild-to-moderate persistent asthma.
Murphy K; Nelson H; Parasuraman B; Boggs R; Miller C; O'Dowd L
Curr Med Res Opin; 2008 Mar; 24(3):879-94. PubMed ID: 18267051
[TBL] [Abstract][Full Text] [Related]
22. A review of the development of Respimat Soft Mist Inhaler.
Dalby R; Spallek M; Voshaar T
Int J Pharm; 2004 Sep; 283(1-2):1-9. PubMed ID: 15363496
[TBL] [Abstract][Full Text] [Related]
23. Performance of pressurized metered-dose inhalers at extreme temperature conditions.
Morin CMD; Ivey JW; Titosky JTF; Suderman JD; Olfert JS; Vehring R; Finlay WH
J Pharm Sci; 2014 Nov; 103(11):3553-3559. PubMed ID: 25252183
[TBL] [Abstract][Full Text] [Related]
24. Towards the bioequivalence of pressurised metered dose inhalers 2. Aerodynamically equivalent particles (with and without glycerol) exhibit different biopharmaceutical profiles in vitro.
Haghi M; Bebawy M; Colombo P; Forbes B; Lewis DA; Salama R; Traini D; Young PM
Eur J Pharm Biopharm; 2014 Jan; 86(1):38-45. PubMed ID: 23528797
[TBL] [Abstract][Full Text] [Related]
25. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
[TBL] [Abstract][Full Text] [Related]
26. Comparative in vitro performance of three small-volume valved holding chambers with beclomethasone/formoterol pressurized metered dose inhaler.
Goncalves TM; Alhanout K; Nicolay A; Dubus JC; de Santana DP; Andrieu V
J Aerosol Med Pulm Drug Deliv; 2013 Aug; 26(4):223-7. PubMed ID: 23094686
[TBL] [Abstract][Full Text] [Related]
27. A correlation equation for the mass median aerodynamic diameter of the aerosol emitted by solution metered dose inhalers.
Ivey JW; Lewis D; Church T; Finlay WH; Vehring R
Int J Pharm; 2014 Apr; 465(1-2):18-24. PubMed ID: 24524827
[TBL] [Abstract][Full Text] [Related]
28. A model for predicting size distributions delivered from pMDIs with suspended drug.
Stein SW; Sheth P; Myrdal PB
Int J Pharm; 2012 Jan; 422(1-2):101-15. PubMed ID: 22044537
[TBL] [Abstract][Full Text] [Related]
29. Variability in Delivered Dose from Pressurized Metered-Dose Inhaler Formulations Due to a Delay Between Shake and Fire.
Hatley RH; Parker J; Pritchard JN; von Hollen D
J Aerosol Med Pulm Drug Deliv; 2017 Feb; 30(1):71-79. PubMed ID: 27635793
[TBL] [Abstract][Full Text] [Related]
30. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial.
Calverley PM; Kuna P; Monsó E; Costantini M; Petruzzelli S; Sergio F; Varoli G; Papi A; Brusasco V
Respir Med; 2010 Dec; 104(12):1858-68. PubMed ID: 20965712
[TBL] [Abstract][Full Text] [Related]
31. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
Berger WE; Noonan MJ
J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
[TBL] [Abstract][Full Text] [Related]
32. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients.
Busse WW; Shah SR; Somerville L; Parasuraman B; Martin P; Goldman M
J Allergy Clin Immunol; 2008 Jun; 121(6):1407-14, 1414.e1-6. PubMed ID: 18455221
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of adjustable maintenance dosing with budesonide/formoterol turbuhaler compared with traditional fixed doses in bronchial asthma: a multi-centre Nigerian study.
Ige OM; Ohaju-Obodo JO; Chukwu C; Peters EJ; Okpapi J; Chukwuka C
Afr J Med Med Sci; 2010 Sep; 39(3):165-72. PubMed ID: 21416785
[TBL] [Abstract][Full Text] [Related]
34. Symbicort: a pharmacoeconomic review.
Halpin DM
J Med Econ; 2008; 11(2):345-62. PubMed ID: 19450091
[TBL] [Abstract][Full Text] [Related]
35. Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases.
Ferguson GT; Hickey AJ; Dwivedi S
Respir Med; 2018 Jan; 134():16-23. PubMed ID: 29413503
[TBL] [Abstract][Full Text] [Related]
36. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
Lindberg A; Szalai Z; Pullerits T; Radeczky E
Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
[TBL] [Abstract][Full Text] [Related]
37. Inhaled formoterol versus ipratropium bromide in chronic obstructive pulmonary disease.
Chhabra SK; Vijayan VK; Vasu T
Indian J Chest Dis Allied Sci; 2006; 48(2):97-102. PubMed ID: 16696522
[TBL] [Abstract][Full Text] [Related]
38. Early bronchodilatory effects of budesonide/formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids.
Hampel FC; Martin P; Mezzanotte WS
J Asthma; 2008 May; 45(4):265-72. PubMed ID: 18446589
[TBL] [Abstract][Full Text] [Related]
39. Characterization of suspension-based metered dose inhaler formulations composed of spray-dried budesonide microcrystals dispersed in HFA-134a.
Tarara TE; Hartman MS; Gill H; Kennedy AA; Weers JG
Pharm Res; 2004 Sep; 21(9):1607-14. PubMed ID: 15497686
[TBL] [Abstract][Full Text] [Related]
40. Impact of droplet evaporation rate on resulting in vitro performance parameters of pressurized metered dose inhalers.
Sheth P; Grimes MR; Stein SW; Myrdal PB
Int J Pharm; 2017 Aug; 528(1-2):360-371. PubMed ID: 28599855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
